Abstract
Background: Asthma is the most common chronic respiratory condition in children, who may have uncontrolled disease despite maximal therapy. Type 2 (T2) inflammation (blood eosinophils ≥150 cells/µL or FeNO ≥20 ppb) underlies most pediatric asthma. Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL-4/13, key and central drivers of T2 inflammation. VOYAGE, a 52-week randomized, double-blind, placebo (PBO)-controlled phase 3 study (NCT02948959), evaluated DPL efficacy/safety in children aged 6–11 years with uncontrolled persistent asthma.
Aim: Assess DPL impact on asthma control (ACQ-7-IA) and health-related quality of life (HRQoL; PAQLQ[S]-IA) in VOYAGE T2 patients (pts).
Methods: Change from baseline in ACQ-7-IA/PAQLQ[S]-IA scores, percentage of responders (improvement ≥0.5) or pts who achieved well-controlled asthma (ACQ-7-IA score ≤0.75).
Results: DPL vs PBO rapidly improved asthma control by Week (Wk)4 and was sustained to Wk52 (P<0.05). At Wk24, 79% DPL vs 69% PBO pts were ACQ-7-IA responders and 61% DPL vs 43% PBO achieved well-controlled asthma (P<0.05). From Wk36, DPL vs PBO significantly improved PAQLQ[S]-IA scores across all domains—symptoms, activity limitation, emotional. A higher proportion of DPL vs PBO pts were PAQLQ[S]-IA responders at Wk52 (P<0.05; Figure).
Conclusion: In children with uncontrolled T2 asthma, DPL rapidly improved asthma control. HRQoL also improved over time.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3920.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
